These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 22300068)
1. Adherence with migraine prophylaxis in clinical practice. Berger A; Bloudek LM; Varon SF; Oster G Pain Pract; 2012 Sep; 12(7):541-9. PubMed ID: 22300068 [TBL] [Abstract][Full Text] [Related]
2. Incidence and determinants of migraine prophylactic medication in the Netherlands. Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC Eur J Clin Pharmacol; 2002 May; 58(2):149-55. PubMed ID: 12012149 [TBL] [Abstract][Full Text] [Related]
3. Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States. Woolley JM; Bonafede MM; Maiese BA; Lenz RA Headache; 2017 Oct; 57(9):1399-1408. PubMed ID: 28842990 [TBL] [Abstract][Full Text] [Related]
4. Beliefs about medicines and adherence among Swedish migraineurs. Hedenrud T; Jonsson P; Linde M Ann Pharmacother; 2008 Jan; 42(1):39-45. PubMed ID: 18073328 [TBL] [Abstract][Full Text] [Related]
6. Adherence to oral migraine-preventive medications among patients with chronic migraine. Hepp Z; Dodick DW; Varon SF; Gillard P; Hansen RN; Devine EB Cephalalgia; 2015 May; 35(6):478-88. PubMed ID: 25164920 [TBL] [Abstract][Full Text] [Related]
7. The use of migraine preventive medications among patients with and without migraine headaches. Lafata JE; Tunceli O; Cerghet M; Sharma KP; Lipton RB Cephalalgia; 2010 Jan; 30(1):97-104. PubMed ID: 19489877 [TBL] [Abstract][Full Text] [Related]
8. Influence of disease features on adherence to prophylactic migraine medication. Linde M; Jonsson P; Hedenrud T Acta Neurol Scand; 2008 Dec; 118(6):367-72. PubMed ID: 18513346 [TBL] [Abstract][Full Text] [Related]
10. A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid. Oladapo AO; Barner JC; Rascati KL; Strassels SA Clin Ther; 2012 Mar; 34(3):605-13. PubMed ID: 22386828 [TBL] [Abstract][Full Text] [Related]
11. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs. Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691 [TBL] [Abstract][Full Text] [Related]
13. Weight change associated with the use of migraine-preventive medications. Taylor FR Clin Ther; 2008 Jun; 30(6):1069-80. PubMed ID: 18640463 [TBL] [Abstract][Full Text] [Related]
14. Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database. Ford JH; Schroeder K; Buse DC; Joshi S; Gelwicks S; Foster SA; Aurora SK Curr Med Res Opin; 2020 Jan; 36(1):51-61. PubMed ID: 31422701 [No Abstract] [Full Text] [Related]
15. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]